Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The treatment of degenerative prosthetic aortic valves is increasingly important. However, redo surgical aortic valve replacement (Re-SAVR) carries higher perioperative risks than primary surgical aortic valve replacement.
Aim: This study aims to identify predictors of early morbidity and death after Re-SAVR.
Methods: A retrospective analysis of 220 patients scheduled for elective Re-SAVR between 2009 and 2017 was conducted. Patients were divided into isolated (n=87) and combined (n=133) redo procedures. The primary endpoint was in-hospital death, and secondary endpoints were postoperative complications, such as stroke, dialysis and pacemaker implantation. Regression analysis identified independent predictors of death.
Results: Among the patients undergoing Re-SAVR (mean age, 62.6±13.2years; 71% male; mean EuroSCORE II, 12.6±11.1%), 86.4% received biological prostheses and 13.6% received mechanical prostheses. The in-hospital death rate was 5.7% for isolated Re-SAVR and 18.0% for combined procedures (P=0.003). Excluding patients with endocarditis, the in-hospital death rate was 0% for isolated Re-SAVR and 19.7% for combined procedures (P=0.002). The incidence of postoperative complications after an isolated procedure was similar to that after a combined procedure. Independent predictors of 30-day death were previous coronary artery bypass grafting (odds ratio: 14.12, 95% confidence interval: 4.40-51.35; P<0.001), a combined procedure (odds ratio: 7.01, 95% confidence interval: 2.09-31.54; P=0.004) and New York Heart Association functional class III/IV (odds ratio: 3.73, 95% confidence interval: 1.31-12.58; P=0.020).
Conclusions: The perioperative risk of death after isolated Re-SAVR in patients without endocarditis was 0%. Independent predictors of in-hospital death included previous coronary artery bypass grafting, combined procedures and New York Heart Association class III/IV. These findings may inform the decision-making process of the heart team regarding the optimal approach (surgical or transcatheter) for redo aortic valve replacement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acvd.2025.05.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Spontaneous Aortic Sealing with Tranexamic Acid in Type A Dissection: A Novel Life-Saving Finding.
Eur J Case Rep Intern Med
August 2025
Department of Gastroenterology and Hepatology, University of Balamand, Beirut, Lebanon.
Unlabelled: Aortic dissection is a life-threatening cardiovascular emergency, particularly Stanford type A, which typically necessitates urgent surgical intervention. Despite advances in surgical techniques and perioperative care, preoperative bleeding and coagulopathy remain significant challenges. Tranexamic acid, an antifibrinolytic agent, is widely used to minimize perioperative bleeding in cardiovascular surgeries; however, its role in the non-surgical, preoperative stabilization of aortic dissection has not been well established.
View Article and Find Full Text PDFTotally endoscopic mitral valve replacement for mitral regurgitation post-transcatheter aortic valve implantation: a case report.
Eur Heart J Case Rep
September 2025
Department of Cardiology, Toyohashi Heart Center, 21-1 Gobutori, Oyamacho, Toyohashi 441-8530, Japan.
Background: Mitral regurgitation (MR) may rarely worsen after transcatheter aortic valve implantation (TAVI) due to mechanical interference from the transcatheter heart valve (THV). Standard surgical approaches in these cases are often challenging due to anatomical constraints. Thus, there is a need for the development of effective alternatives to address this issue.
View Article and Find Full Text PDFMinimally Invasive or Conventional Sternotomy for Mitral Valve Surgery With Concomitant Surgical Ablation for Atrial Fibrillation: A Comparative Systematic Review.
Rev Cardiovasc Med
August 2025
E. Meshalkin National Medical Research Center, Institute of Cardiovascular Pathology Research, 630055 Novosibirsk, Russian Federation.
Background: Presently, the availability of single-stage surgical correction of mitral valve disease combined with atrial fibrillation (AF) via a mini-access approach remains limited. Moreover, the comparative effectiveness of this procedure versus conventional sternotomy (CS) remains poorly understood. Thus, this study aimed to conduct a comparative assessment of the efficacy and safety of concomitant mitral valve surgery and AF ablation via a minimally invasive approach (minimally invasive cardiac surgery, MICS group) versus the standard sternotomy approach (CS group).
View Article and Find Full Text PDFShort-Term Outcomes Following Transcatheter Valve-in-Valve Implantation With Portico or Navitor Valves: The Barts Heart Center Experience.
Catheter Cardiovasc Interv
September 2025
Department of Cardiology, Barts Heart Center, Barts Health NHS Trust, London, UK.
Background: Degeneration of surgical bioprosthetic aortic valves is increasingly common. Redo surgical aortic valve replacement carries substantial morbidity and mortality, particularly in elderly or high-risk patients. Valve-in-valve (ViV) transcatheter aortic valve implantation (TAVI) has become an established alternative, though data on the performance of self-expanding Portico and Navitor valves remain limited.
View Article and Find Full Text PDFOutcomes of resuscitative endovascular balloon occlusion of the aorta (REBOA) in severely injured adult trauma patients with isolated thoracic or abdominal trauma in Hemorrhagic shock.
Am J Emerg Med
September 2025
Department of Surgical Education, Orlando Regional Medical Center, Orlando, FL, USA; Department of Surgery, Division of Trauma and Surgical Critical Care, Orlando Regional Medical Center, Orlando, FL, USA. Electronic address:
Background: There is conflicting literature regarding mortality outcomes associated with REBOA usage in patients with severe thoracic or abdominal trauma. Our study aims to assess the benefits and negative implications of REBOA use in adult trauma patients in hemorrhagic shock with severe thoracic or abdominal injuries.
Methods: This retrospective cohort analysis utilized the American College of Surgeons Trauma Quality Improvement Program Participant Use File (ACS-TQIP-PUF) database from 2017 to 2023 to evaluate adult patients with severe isolated thoracic or abdominal trauma undergoing REBOA placement.